Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancersurgery.
Intraperitoneal therapy
NanoPac
Ovarian cancer
Paclitaxel
Submicron particle paclitaxel
Journal
Gynecologic oncology reports
ISSN: 2352-5789
Titre abrégé: Gynecol Oncol Rep
Pays: Netherlands
ID NLM: 101652231
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
04
05
2020
revised:
13
08
2020
accepted:
18
08
2020
entrez:
21
9
2020
pubmed:
22
9
2020
medline:
22
9
2020
Statut:
epublish
Résumé
Submicron particles (~800 nm) of paclitaxel (SPP) contain 1-2 billion molecules of pure drug that release tumoricidal levels of paclitaxel over many weeks. This study compared two dose-levels of SPP instilled into the peritoneal cavity (IP) in 200 ml of saline post-cytoreductive surgery. Eligible patients with primary (n = 6) or recurrent (n = 4) epithelial ovarian cancer who underwent complete cytoreductive surgery were enrolled to receive a single instillation of IP SPP followed by standard IV carboplatin and paclitaxel. Endpoints were PFS and evaluation of treatment emergent adverse events. Clinical response was determined by symptoms, physical exams, CT scans, and serum CA-125 measurements. Of the 24 subjects screened, 10 were enrolled and received treatment: seven patients received 100 mg/m
Identifiants
pubmed: 32953961
doi: 10.1016/j.gore.2020.100627
pii: S2352-5789(20)30093-X
pmc: PMC7486435
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100627Informations de copyright
© 2020 The Author(s).
Déclaration de conflit d'intérêts
Sally Mullany: nothing to disclose David Scott Miller: non-financial support from US Biotest. Katina Robison: nothing to disclose Kimberly Levinson: nothing to disclose Yi-Chun Lee: nothing to disclose S. Diane Yamada: non-financial support from US Biotest. Joan Walker: nothing to disclose Maurie Markman: personal fees from NanOlogy, outside the submitted work. Gere diZerega: personal fees and non-financial support from NanOlogy and US Biotest. Alyson Marin: personal fees from US Biotest. Peter Mast: personal fees from US Biotest.
Références
Cancer. 2019 Dec 15;125 Suppl 24:4582-4586
pubmed: 31967679
Ann Oncol. 2017 Nov 1;28(suppl_8):viii46-viii50
pubmed: 29232475
Cancer Chemother Pharmacol. 2019 Mar;83(3):589-598
pubmed: 30623229
J Clin Oncol. 1992 Sep;10(9):1485-91
pubmed: 1355523
J Aerosol Med Pulm Drug Deliv. 2019 Apr;32(2):99-109
pubmed: 30359162
J Clin Oncol. 2019 Sep 20;37(27):2416-2419
pubmed: 31403863
Ann Oncol. 2017 Nov 1;28(suppl_8):viii40-viii45
pubmed: 29232474
J Pharm Pharmacol. 2002 Feb;54(2):159-80
pubmed: 11848280
Oncologist. 2008 Apr;13(4):403-9
pubmed: 18448554
Cancer. 2019 Dec 15;125 Suppl 24:4623-4629
pubmed: 31967682
Cancer Chemother Pharmacol. 2015 May;75(5):1075-87
pubmed: 25898813